A Single-Arm, Single-Site, Single-Dose Phase 1 Study Assessing the Safety of Bryostatin in the Treatment of Patients With Multiple Sclerosis
Latest Information Update: 01 May 2025
At a glance
- Drugs Bryostatin-1 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
Most Recent Events
- 24 Apr 2025 Planned End Date changed from 1 Aug 2026 to 15 Jul 2026.
- 24 Apr 2025 Planned primary completion date changed from 1 Apr 2026 to 15 Jun 2026.
- 10 Jan 2025 Status changed from recruiting to active, no longer recruiting.